Current　antithrombotic　therapeutic　strategies　often　suffer　from　severe　post-thrombotic　syndromes　(PTS),　inconvenient　daily　subcutaneous　injections　for　a　long　time　and　short　circulation　times　accompanied　by　a　dose-dependent　risk　of　intracranial　hemorrhage.　Aiming　at　noninvasive,　on-demand,　and　sustained　antithrombotic　therapy,　a　new　thrombolysis　approach　based　on　the　transgene　system　has　been　developed　to　remotely　and　precisely　control　the　expression　of　urokinase　plasminogen　activator　(uPA)　by　bioengineered　cells　for　antithrombotic　therapy　both　in　vitro　and　in　vivo.　In　this　design,　the　near-infrared　(NIR)　light　could　activate　the　expression　of　the　thermosensitive　TRPV1　channel　in　response　to　photothermal　responsive　nanotransducers　to　trigger　the　synthetic　signaling　pathway　to　secret　uPA.　By　encapsulating　bioengineered　cells　in　injectable　hydrogel　to　ensure　long-term　survival　and　convenience　for　injection,　the　engineered　cells　could　noninvasively　and　precisely　control　the　production　of　uPA　protein　in　situ　via　an　NIR　laser　to　significantly　enhance　the　thrombolysis　therapeutic　effects　by　spatiotemporally　controlling　the　local　temperature,　in　both　the　microfluidic　blood　circulation　mimic　and　the　murine　tail　thrombus　model.　This　novel　thrombolysis　approach　could　overcome　some　key　limitations　that　are　associated　with　conventional　antithrombotic　therapy,　thus　opening　a　new　direction　for　developing　remotely　and　precisely　controllable　continuous　thrombolysis　through　artificially　designed　signaling.